Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (53): 9921-9924.doi: 10.3969/j.issn.1673-8225.2010.53.010

Previous Articles     Next Articles

Reduction of hepatitis B recurrence after liver transplantation using hepatitis B immunoglobulin combined with nucleoside analogs

Li Zhu, Li Li, Ran Jiang-hua, Zhang Sheng-ning, Liu Jing, Li Lai-bang, Liu Dian-sheng, Wu Shu-yuan, Chen Juan   

  1. The First Hospital of Kunming, Affiliated Ganmei Hospital of Kunming Medical College, Kunming  650011, Yunnan Province, China
  • Online:2010-12-31 Published:2010-12-31
  • About author:Li Zhu☆, Doctor, Attending physician, the First Hospital of Kunming, Affiliated Ganmei Hospital of Kunming Medical College, Kunming 650011, Yunnan Province, China kmlizhu@126.com

PDF

315

Abstract:

BACKGROUND: There is not a united method for preventing and treating hepatitis B recurrence after liver transplantation.
OBJECTIVE: To investigate the control plans of hepatitis B recurrence after liver transplantation.
METHODS: Totally 117 liver transplantation recipients with liver cirrhosis after chronic hepatitis B were analyzed retrospectively. Using three therapeutic scheme, the patients were divided into 5 groups according to the received treatment time: adefovir dipivoxil plus low dose hepatitis B immunoglobulin (HBIG) short-term group (group A), adefovir dipivoxil plus high dose HBIG mid-long-term group (group B, group B+), entecavir plus suitable dose HBIG individual therapy group (group C, group C+). Then the cumulating effective inhibition rate and powerful inhibition rate of HBV were observed. All of patients were followed-up 2 years at least.
RESULTS AND CONCLUSION: The cumulating effective inhibition rate and powerful inhibition rate of HBV in group B, B+, C and C+ were much higher than that in group A (P < 0.05). The therapeutic effect of hepatitis B in groups C, C+ were better than that in group B, B+ respectively (P < 0.05). The results demonstrated that prevention of hepatitis B recurrence after liver transplantation is a long-term, even for a life time process, suitable dose of HBIG combined with antiviral drug is benefit for the prevention and cure of hepatitis B recurrence.

CLC Number: